How Changing Your Diet Could Have a Major Impact on Managing Lupus Symptoms
After Jewell Singletary was diagnosed with lupus, she developed rheumatoid arthritis as well—a common pairing, since both are autoimmune conditions—and had to use a cane to navigate her college campus. When she graduated, the now 38-year-old New Jersey resident decided to be more focused on supporting her health, in an effort to maintain her mobility as she began her career.
She started in the kitchen.
First to be tossed were sugary drinks, fried foods, and highly processed options, she says. Once she eliminated them, it didn’t take long before she could discard one more important item: her cane.
[time-br...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Diet & Nutrition freelance healthscienceclimate Source Type: news
Corticosteroids
Title: CorticosteroidsCategory: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/24/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 24, 2022 Category: Dermatology Source Type: news
What to Know About the Latest Advances in Managing Severe Asthma
Graphs and charts don’t always tell the whole story. Numbers can be deceiving. But anyone who looks at U.S. trends in asthma mortality can see, without squinting, that things are moving in the right direction.
A 2019 analysis in the American Journal of Respiratory and Critical Care Medicine found that from 1999 to 2015, asthma mortality fell by 43%. “The decrease in asthma-related mortality was consistent in both sexes and in all race groups, with the largest decrease in patients older than 65 years,” the authors concluded. Figures from the U.S. Centers for Disease Control and Prevention indicate that the...
Source: TIME: Health - June 23, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Recommended Drugs for Headache Rarely Prescribed in EDs Recommended Drugs for Headache Rarely Prescribed in EDs
Although guidelines caution against it, use of diphenhydramine in EDs more than doubled over a recent 11-year period, but recommended drugs such as triptans and corticosteroids were rarely prescribed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Watch Out for Common Misconceptions About Atopic Dermatitis Watch Out for Common Misconceptions About Atopic Dermatitis
A fear of corticosteroids sometimes prompts patients to try alternative treatments, some of which can be harmful. A pharmacist explains how clinicians can improve treatment by educating patients.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 15, 2022 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2022 Category: Drugs & Pharmacology Source Type: news
Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Trial Upends Guidelines on Long-Term Steroids in Rheumatoid Arthritis
(MedPage Today) -- COPENHAGEN -- A randomized trial reported here appears to confirm that, contrary to guidance from major rheumatology societies, years-long use of corticosteroids in older rheumatoid arthritis (RA) patients is both effective... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - June 3, 2022 Category: Rheumatology Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Prophylaxis for PJP in Patients With Sarcoidosis Prophylaxis for PJP in Patients With Sarcoidosis
Dr Aaron Holley scrutinizes the practice of prescribing TMP-SMX to preventPneumocystis jirovecii pneumonia in patients on oral corticosteroids for sarcoidosis.Medscape Critical Care (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 24, 2022 Category: Infectious Diseases Tags: Critical Care Viewpoint Source Type: news
Triple Therapy for COPD: One Drug Too Many, Too Often?
(MedPage Today) -- SAN FRANCISCO -- Patients with chronic obstructive pulmonary disease (COPD) who changed treatment from so-called triple therapy to a two-drug product omitting the inhaled corticosteroid (ICS) component tended to see improved... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - May 19, 2022 Category: Allergy & Immunology Source Type: news
